Get intelligentvalue.com

Own it today or select a payment plan

Secured by Stripe

Premium Domain Name

intelligentvalue.com

intelligentvalue.com logo

is available for purchase

51 views
Visitors fromUSUS 54%·AUAU 32%·ININ 7%·GBGB 2%·FRFR 2%

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

VisaMastercardAmerican ExpressDiscoverDiners ClubJCBApple PayGoogle Pay

Precision BioSciences to Present at Upcoming Sidoti Conference

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the Company will present at the Sidoti November Micro Cap Conference taking place November 15-16, 2023.

Details for the presentation are as follows:

Date: November 15, 2023

Time: 10:45 AM ET

The presentation will be available on Precision’s website under the Investors section under Events & Presentations on November 15, 2023 at investor.precisionbiosciences.com. An archived replay will be available for approximately 30 days following the event.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  246.02
+0.00 (0.00%)
AAPL  296.42
+0.00 (0.00%)
AMD  547.26
+0.00 (0.00%)
BAC  55.87
+0.00 (0.00%)
GOOG  367.11
+0.00 (0.00%)
META  593.48
+0.00 (0.00%)
MSFT  399.76
+0.00 (0.00%)
NVDA  212.45
+0.00 (0.00%)
ORCL  192.64
+0.00 (0.00%)
TSLA  411.15
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.